NCT02195791

Neuroprotection of Pioglitazone in Acute Ischemic Stroke

Mechanism of Hyperglycemia and Neuroprotection Effect of Pioglitazone in Acute Ischemic Stroke

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 4 (actual)
• Sponsor: Taipei Medical University Shuang Ho Hospital · Academic / Other
• Sex: All
• Age: 20 Years
• Healthy volunteers: Not accepted

Summary

Pioglitzone, an oral anti-diabetic drug which can reduce insulin resistance and decrease inflammation. It has been proven to be an effective neuroprotective agent in animal model of ischemic stroke. In this study, the investigators will conduct a phase II clinical trial (double-blind, randomized placebo controlled study) to survey the neuroprotection effect of pioglitazone in stroke patients with hyperglycemia. A total of 152 acute ischemic stroke patients with hyperglycemic will receive insulin or sulfonyurea for blood sugar control, and will be randomly randomized into intervention (Pioglitazone 30mg once a day p.o,) and control group (placebo). The investigators expect to prove the neuroprotective efficacy of Pioglitazone in acute stroke with hyperglycemia and identify the biomarkers associated with good neurological outcome in patients with Pioglitazone treatment from the investigators clinical trial.

Conditions

• Stroke

Interventions

Type	Name	Description
DRUG	Pioglitazone	Pioglitazone 30mg/tab (oral) 1 tab once daily for 7 days
DRUG	Placebo	Placebo (oral) 1 tab once daily for 7 days

Timeline

• Start date: 2014-07-01
• Primary completion: 2016-08-01
• Completion: 2016-08-01
• First posted: 2014-07-21
• Last updated: 2017-01-20

Locations

1 site across 1 country: Taiwan